Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Denmark: COPSAC, Copenhagen Prospective Study of Childhood Asthma, researchers in Copenhagen, Denmark, noted that a higher risk...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.
2.
Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.
3.
Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs
4.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
5.
If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version
1.
What is Red Cell Distribution Width and Why Should You Care?
2.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
3.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge